Search | Clinical Trials Finder

Conditions: Head and Neck Cancer
Interventions: ASP-1929 Photoimmunotherapy, Physician's Choice SOC; Combination Product · Drug
Lead sponsor: Rakuten Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 7
States / cities: Miami, Florida • Tampa, Florida • Atlanta, Georgia + 3 more

Conditions: Wounds and Injuries
Interventions: AR/101, Placebo; Drug
Lead sponsor: Arava Bio Tech Ltd.; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Advanced Non-small Cell Lung Cancer, HER2 Mutation
Interventions: Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 25
States / cities: Newport Beach, California • San Diego, California • San Francisco, California + 20 more

Conditions: Acute Respiratory Infections (ARIs)
Interventions: SPOTFIRE R/ST Diagnostic Test; Device
Lead sponsor: BioMérieux; Industry
Eligibility: 1 Year and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Gardendale, Alabama • Hoover, Alabama

Conditions: Knee Replacement Surgery, Osteoarthritis
Interventions: Standard of Care, FLOSEAL Hemostatic Matrix + Standard of care; Procedure · Drug
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 12
States / cities: Los Angeles, California • Redwood City, California • Englewood, Colorado + 8 more

Conditions: HIV Infections
Interventions: VH4524184, Matching Placebo, Antiretroviral therapy; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 5
States / cities: Bakersfield, California • Los Angeles, California • West Hollywood, California + 2 more

Conditions: Surgical Site Infection, Sternal Infection, Cardiac Surgery
Interventions: D-PLEX, Standard of Care; Drug · Other
Lead sponsor: PolyPid Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Rochester, Minnesota • Huston, Texas

Conditions: Pulmonary Aspergillosis
Interventions: Opelconazole, Standard of Care; Drug
Lead sponsor: Pulmocide Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 17
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 11 more

Conditions: Chronic Diabetic Foot Ulcers
Interventions: Dual Layer Amniotic Membrane (DLAM). Artacent®; Biological
Lead sponsor: SerenaGroup, Inc.; Network
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 15
States / cities: Phoenix, Arizona • Los Angeles, California • Pembroke Pines, Florida + 12 more

Conditions: Wound Heal, Ulcer
Interventions: InnovaMatrix® AC; Device
Lead sponsor: ConvaTec Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 21
States / cities: Fresno, California • Los Angeles, California • San Diego, California + 16 more

Conditions: ARDS, Human, Lung, Wet, Thyroid, Pulmonary Edema, Lung Inflammation
Interventions: Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation., Non-intervention; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Edina, Minnesota • Minneapolis, Minnesota

Conditions: Type 2 Diabetes Mellitus
Interventions: Use of digital disease management tool; Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 46
States / cities: Birmingham, Alabama • Peoria, Arizona • Surprise, Arizona + 41 more

Conditions: Venous Leg Ulcer, Venous Leg, Diabetic Foot, Diabetic Foot Ulcer, Foot Ulcer, Diabetic, Ulcer Foot, Leg Ulcer, Ulcer Venous, Ulcer
Interventions: ACApatch™, caregraFT™, Standard of Care; Other
Lead sponsor: Tiger Biosciences, LLC.; Industry
Eligibility: 21 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Monroeville, Pennsylvania

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: 177Lu-TLX591, Enzalutamide, Abiraterone, Docetaxel; Drug
Lead sponsor: Telix Pharmaceuticals (Innovations) Pty Limited; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 9
States / cities: Orange, California • Miami, Florida • Glen Burnie, Maryland + 6 more

Conditions: Prostate Carcinoma
Interventions: Targeted Prostate Biopsy, Prostate Imaging Reporting & Data System, Deep Learning Artificial Intelligence, Green Learning Artificial Intelligence, Radical Prostatectomy; Procedure · Diagnostic Test
Lead sponsor: University of Southern California; Other
Eligibility: 20 Years and older · Male only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: COVID-19, Sars-CoV2
Interventions: Progesterone 100 MG; Drug
Lead sponsor: Sara Ghandehari; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Venous Leg Ulcer, Chronic Wounds
Interventions: Hyalomatrix, Standard of Care; Device · Other
Lead sponsor: NuScience Medical Biologics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Alexandria, Louisiana • Pineville, Louisiana • Vidalia, Louisiana + 1 more

Conditions: Diabetic Foot Ulcers (DFUs), Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer)
Interventions: Miro3D Wound Matrix, Standard of Care (SOC); Device · Other
Lead sponsor: Reprise Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Coconut Creek, Florida • Tamarac, Florida • New York, New York

Conditions: Patient Adherence, HIV Seronegativity
Interventions: brief Motivational Interviewing; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 263 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Los Angeles, California • San Diego, California • Torrance, California

Conditions: Wound
Interventions: Standard of Care Treatment or Standard of Care Treatment plus Miro3D Wound Matrix; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 90 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hematopoietic and Lymphatic System Neoplasm
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Axatilimab, Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography, Cyclophosphamide, Magnetic Resonance Imaging, Mycophenolate Mofetil, Placebo Administration, Positron Emission Tomography, Skin Biopsy, Tacrolimus, X-Ray Imaging; Procedure · Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Autoimmune Hepatitis, AIH
Interventions: Inebilizumab, Placebo, Standard of Care; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 6
States / cities: Little Rock, Arkansas • Northridge, California • Rialto, California + 3 more

Conditions: Diabetic Foot Ulcer
Interventions: NuShield; Other
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 9
States / cities: Carlsbad, California • Fresno, California • Los Angeles, California + 6 more

Conditions: COVID-19
Interventions: FSD201, Placebo, Standard of Care for Covid-19; Drug · Other
Lead sponsor: Quantum Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: Miami, Florida • St. Petersburg, Florida • Idaho Falls, Idaho + 6 more

Search by objective public record fields.

ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

Safety and Efficacy of AR/101 in Accelerating Re-epithelialization of Split Thickness Wounds

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Impact of a Multiplex Respiratory PCR Test on Outcomes for Patients Presenting With Respiratory Illness in the Urgent Care Setting: A Hybrid-Effectiveness Quasi-Experimental Trial

Efficacy and Safety of FLOSEAL for Hemostasis in Total Knee Arthroplasty

VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1

D-PLEX 302: Efficacy and Safety of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery

An Open-label Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)

Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®)

IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers

Treatment of ARDS With Instilled T3

A 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With T2DM

Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot and Venous Leg Ulcers.

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

MRI-Based Machine Learning Approach Versus Radiologist MRI Reading for the Detection of Prostate Cancer, The PRIMER Trial

Progesterone for the Treatment of COVID-19 in Hospitalized Men

Evaluation of the Efficacy of Hyalomatrix® in the Healing of Chronic Venous Leg Ulcers

Miro3D Wound Matrix Study for Diabetic Foot Ulcers and Wound Healing

Randomized Controlled Trial of iTAB Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals

Miro3D Randomized Controlled Trial (RCT)

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

A Trial of Inebilizumab in Participants With Autoimmune Hepatitis

Randomized Clinical Study Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers

Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19